Thursday, February 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analysts Adjust Price Targets for Stericycle Inc Following Mixed Q4 Results

Elaine Mendonca by Elaine Mendonca
February 29, 2024
in Breaking News
0
Finance_Assets (2)
0
SHARES
7
VIEWS
Share on FacebookShare on Twitter

Following Stericycle, Inc.’s (NASDAQ: SRCL) release of its fourth-quarter financial results on February 29, 2024, analysts made changes to their forecasts and price targets for the company. The results were a mixed bag, with adjusted earnings per share coming in at 54 cents, exceeding market expectations, but quarterly sales of $652.00 million falling short.

Income from operations decreased to $37.1 million in the fourth quarter, down from $59.1 million the previous year. Stericycle’s President and CEO, Cindy J. Miller, emphasized the company’s progress in achieving key business priorities in 2023, such as enhancing efficiency and optimizing the portfolio.

In response to the quarterly results, several analysts adjusted their price targets for Stericycle:
– Truist Securities raised the price target to $57 from $50, maintaining a Hold rating.
– Stifel increased the price target to $75 from $70, with a Buy rating.
– RBC Capital raised the price target to $69 from $58, with an Outperform rating.

Despite these changes, the average one-year price target for Stericycle stands at approximately $54.50, with forecasts ranging from $40.4 to $73.5. On February 29th, the stock was trading at $55.65 per share, above the average analyst 12-month target price of $54.50.

Stericycle Inc. (SRCL) Stock Price Drops Slightly on February 29, 2024 – Analysis and Overview

On February 29, 2024, Stericycle Inc. (SRCL) experienced a slight drop in its stock price, closing at $55.69. Despite this decrease, the company is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating overall strength in the stock.

SRCL opened at $57.06, which was $1.41 higher than its previous close. However, throughout the day, the stock saw a decrease of $1.37, resulting in a 2.47% drop by the time the market closed. This fluctuation in price could be attributed to various factors such as market conditions, industry trends, or company-specific news.

SRCL Stock Performance Analysis: Strong Improvements in Net Income and EPS Despite Flat Revenue Growth

On February 29, 2024, SRCL stock had a mixed performance based on the financial data provided by CNN Money. The company’s total revenue for the past year was $2.70 billion, which remained flat compared to the previous year. Similarly, the total revenue for the third quarter of the year was $653.50 million, also showing no growth compared to the previous quarter.

However, despite the stagnant revenue growth, SRCL showed significant improvement in its net income. The net income for the past year was $56.00 million, marking a 301.44% increase compared to the previous year. In the third quarter, the net income was $2.00 million, showing a 104.04% increase compared to the previous quarter.

Furthermore, the earnings per share (EPS) also saw a positive trend for SRCL. The EPS for the past year was $0.61, reflecting a 300.17% increase compared to the previous year. In the third quarter, the EPS was $0.02, showing a 104.02% increase compared to the previous quarter.

Overall, despite the flat revenue growth, SRCL demonstrated strong improvements in its net income and earnings per share. Investors may view these positive financial indicators as a sign of a potentially promising future for the company. However, it is important to conduct further research and analysis before making any investment decisions based on this information.

Tags: SRCL
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

Revolutionizing Cancer Treatment The Rise of LAVA Therapeutics NV

Acknowledgement of Minimum Postage Value

Biotechnology Markets and money

Advancements and Collaborations Propelling LAVA Therapeutics NV into the Future

Recommended

SKYX Platforms Stock

Marriott Partnership Signals Major Breakthrough for SKYX Platforms

5 months ago
Microsoft Stock

Microsoft’s AI Ambition: A High-Stakes Bet on Future Growth

18 hours ago
Turtle Beach Stock

Turtle Beach Forges PlayStation Alliance with New Gaming Headset

5 months ago
FLO stock news

Cemtrex Shares Surge After Halting Trading Due to Circuit Breaker

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

CureVac Delisted Following BioNTech Acquisition Completion

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

NexPoint Residential Trust Sets Date for Annual and Q4 2025 Results

PC Connection Set to Report Full-Year and Fourth Quarter Earnings

Fossil Group Stock Surges Past Key Technical Threshold

NextGen Healthcare: Strategic Wins and Industry Accolades Signal Sustained Momentum

Trending

Rolls Royce Stock
Defense & Aerospace

Rolls-Royce Shares: A Pivotal Period for Growth and Diversification

by Dieter Jaworski
February 5, 2026
0

The coming weeks represent a critical juncture for Rolls-Royce. The company is poised to demonstrate whether it...

Viking Therapeutics Stock

Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report

February 5, 2026
Solana Stock

Solana Faces Billions in Potential Token Supply Releases

February 5, 2026
CureVac Stock

CureVac Delisted Following BioNTech Acquisition Completion

February 5, 2026
EOS Stock

Strategic Robotics Partnership Signals New Growth Phase for EOS Defence

February 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Rolls-Royce Shares: A Pivotal Period for Growth and Diversification
  • Viking Therapeutics: Investors Await Key Clinical Updates in Forthcoming Report
  • Solana Faces Billions in Potential Token Supply Releases

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com